Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes

References

• GLOBOCAN 2020. Available from: https://gco.iarc.fr/. Accessed October 11, 2022.
   Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491 e471.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Hyun JY, Kim SK, Yoon SJ, et al. Microbiome-based metabolic therapeutic approaches in alcoholic liver disease. Int J Mol Sci. 2022;23(15):8749.
   PubMed Web of Science ®Google Scholar
• Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the USA. Curr Gastroenterol Rep. 2019;21(4):17.
   PubMedGoogle Scholar
• Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–1794.
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362.
   PubMed Web of Science ®Google Scholar
• Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022;34(7):969–977 e962. doi:10.1016/j.cmet.2022.05.003
   PubMed Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238. doi:10.1038/s41575-020-00381-6
   PubMed Web of Science ®Google Scholar
• Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2016;1(2):156–164. doi:10.1016/S2468-1253(16)30018-8
   PubMed Web of Science ®Google Scholar
• Da BL, Im GY, Schiano TD. Coronavirus disease 2019 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology. 2020;72(3):1102–1108. doi:10.1002/hep.31307
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Newsroom on hepatitis B. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed October 15, 2022.
   Google Scholar
• Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2). doi:10.1128/CMR.00046-19
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T; European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US – The ENUMERATE study. Aliment Pharmacol Ther. 2016;43(1):134–144. doi:10.1111/apt.13440
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531. doi:10.1056/NEJMoa033364
   PubMed Web of Science ®Google Scholar
• Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol. 2017;11(11):999–1008.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956–967.
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98–107.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306.
   PubMed Web of Science ®Google Scholar
• Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV Infection in China. Gastroenterology. 2020;158(1):215–225 e216.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Wong GL, Chen CH, et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol. 2020;115(2):271–280.
   PubMed Web of Science ®Google Scholar
• Chon HY, Ahn SH, Kim YJ, et al. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol Int. 2021;15(6):1328–1336.
   PubMed Web of Science ®Google Scholar
• Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039–1052.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Atsukawa M, Ishikawa T, et al. Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir. Am J Gastroenterol. 2021;116(6):1264–1273.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Nakamuta M, Koyanagi T, et al. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. 2022;16(2):282–293.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Leong J, Landis C, et al. Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice. Hepatology. 2021;74(2):656–666.
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B. Eur J Gastroenterol Hepatol. 2021;33(1SSuppl 1):e898–e904.
   PubMedGoogle Scholar
• Kaneko S, Kurosaki M, Tamaki N, et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019;34(11):2004–2010.
   PubMed Web of Science ®Google Scholar
• Farag MS, Fung S, Tam E, et al. Effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients: real-world study. J Viral Hepat. 2021;28(6):942–950.
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Shimada S, Kamiyama T, et al. Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection. World J Gastrointest Surg. 2022;14(7):670–684.
   PubMed Web of Science ®Google Scholar
• Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: pathophysiology, prognosis, and treatment challenges. World J Gastroenterol. 2021;27(26):4104–4142.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283.
   PubMed Web of Science ®Google Scholar
• Martin P, Nguyen MH, Dieterich DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update. Clin Gastroenterol Hepatol. 2022;20(8):1766–1775.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61(6):1809–1820.
   PubMed Web of Science ®Google Scholar
• Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57(2):442–450.
   PubMed Web of Science ®Google Scholar
• Terrault N. Is low level viremia acceptable during antiviral therapy of patients with HBV infection and decompensated cirrhosis? Clin Gastroenterol Hepatol. 2018;16(12):1876–1878.
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis. J Viral Hepat. 2021;28(3):508–516.
   PubMed Web of Science ®Google Scholar
• Chen VL, Yeh ML, Le AK, et al. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther. 2018;48(1):44–54.
   PubMed Web of Science ®Google Scholar
• Yeo YH, Nguyen MH. Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States – a call for action. Aliment Pharmacol Ther. 2021;53(1):63–78.
   PubMed Web of Science ®Google Scholar
• Ye Q, Kam LY, Yeo YH, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol. 2022;76(1):63–74.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Yeo YH, Dang N, et al. Diagnosis rates of chronic hepatitis b in privately insured patients in the United States. JAMA Netw Open. 2020;3(4):e201844.
   PubMed Web of Science ®Google Scholar
• Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999–2016. Hepatology. 2020;71(2):431–443.
   PubMed Web of Science ®Google Scholar
• Hou J, Cui F, Ding Y, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2019;17(10):1929–1936 e1921.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva: World Health Organization; 2020.
   Google Scholar
• World Health Organization (WHO). Newsroom on hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed October 31, 2022.
   Google Scholar
• Zou B, Yeo YH, Le MH, et al. Prevalence of viremic hepatitis C virus infection by age, race/ethnicity, and birthplace and disease awareness among viremic persons in the United States, 1999–2016. J Infect Dis. 2020;221(3):408–418.
   PubMed Web of Science ®Google Scholar
• Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology. 2019;69(3):1020–1031.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–148.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485–493.
   PubMed Web of Science ®Google Scholar
• Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64(6):1217–1223.
   PubMed Web of Science ®Google Scholar
• Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71(2):281–288.
   PubMed Web of Science ®Google Scholar
• Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(7):961–967.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Morgan TR; Panel A-IHCG. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721.
   PubMed Web of Science ®Google Scholar
• Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology. 2019;157(5):1253–1263 e1252.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Toyoda H, Iio E, et al. Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: a practice implication. Clin Infect Dis. 2020;71(11):2840–2848.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607.
   PubMed Web of Science ®Google Scholar
• Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, Phase 3 trial. Lancet Infect Dis. 2015;15(6):645–653.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369.
   PubMed Web of Science ®Google Scholar
• Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–1068.
   PubMed Web of Science ®Google Scholar
• Brown RS, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441–449.
   PubMed Web of Science ®Google Scholar
• Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatol. 2019;71(3):473–485.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733.
   PubMed Web of Science ®Google Scholar
• Cheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65(4):741–747.
   PubMed Web of Science ®Google Scholar
• Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69(2):345–352.
   PubMed Web of Science ®Google Scholar
• ANRS collaborative study group on hepatocellular carcinoma, . Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734–740.
   PubMed Web of Science ®Google Scholar
• Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204–1212.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996–1005 e1001.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
   PubMed Web of Science ®Google Scholar
• El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154(8):2111–2121 e2118.
   PubMed Web of Science ®Google Scholar
• Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65(3):804–812.
   PubMed Web of Science ®Google Scholar
• Lusivika-Nzinga C, Fontaine H, Dorival C, et al. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. J Viral Hepat. 2019;26(12):1489–1492.
   PubMed Web of Science ®Google Scholar
• Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017;67(1):32–39.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Degasperi E, Lampertico P. Predicting hepatocellular carcinoma risk in patients with chronic HCV infection and a sustained virological response to direct-acting antivirals. J Hepatocell Carcinoma. 2021;8:713–739.
   PubMed Web of Science ®Google Scholar
• Tsai PC, Kuo HT, Hung CH, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2022;78(2):281–292.
   PubMed Web of Science ®Google Scholar
• Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology. 2016;64(1):47–57.
   PubMed Web of Science ®Google Scholar
• Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31(12):1514–1521.
   PubMed Web of Science ®Google Scholar
• Semmler G, Meyer EL, Kozbial K, et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2022;76(4):812–821.
   PubMed Web of Science ®Google Scholar
• Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–1464.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Ogawa E, Huang CF, et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatol Int. 2020;14(6):1023–1033.
   PubMed Web of Science ®Google Scholar
• Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173–1181.
   PubMed Web of Science ®Google Scholar
• He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51(1):34–52.
   PubMed Web of Science ®Google Scholar
• Chen CY, Huang CF, Cheng PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021;41(6):1265–1277.
   PubMed Web of Science ®Google Scholar
• Dang H, Yeo YH, Yasuda S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology. 2020;71(6):1910–1922.
   PubMed Web of Science ®Google Scholar
• Ito T, Ishigami M, Zou B, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. Hepatol Int. 2021;15(2):366–379.
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904.
   PubMed Web of Science ®Google Scholar
• Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol. 2019;71(2):313–322.
   PubMed Web of Science ®Google Scholar
• Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817 e2828.
   PubMed Web of Science ®Google Scholar
• Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38(10):954–961.
   PubMed Web of Science ®Google Scholar
• Karim MA, Singal AG, Kum HC, et al. Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol. 2022. doi:10.1016/j.cgh.2022.03.010
   Web of Science ®Google Scholar
• Jun TW, Yeh ML, Yang JD, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018;38(5):895–902.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 2021;3(4):100305. doi:10.1016/j.jhepr.2021.100305
   PubMedGoogle Scholar
• Mohamad B, Shah V, Onyshchenko M, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int. 2016;10(4):632–639. doi:10.1007/s12072-015-9679-0
   PubMed Web of Science ®Google Scholar
• Kim NG, Nguyen PP, Dang H, et al. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: a real-world experience from 1998 to 2015. Cancer. 2018;124(12):2588–2598. doi:10.1002/cncr.31373
   PubMed Web of Science ®Google Scholar
• Ito T, Ishigami M, Ishizu Y, et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019;34(1):207–214. doi:10.1111/jgh.14448
   PubMed Web of Science ®Google Scholar
• Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2022;21(2):370–379.
   PubMed Web of Science ®Google Scholar
• Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696–703. doi:10.1111/apt.14937
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549. doi:10.1016/j.jhep.2017.09.016
   PubMed Web of Science ®Google Scholar
• Chavez-Tapia NC, Murua-Beltran Gall S, Ordonez-Vazquez AL, Nuno-Lambarri N, Vidal-Cevallos P, Uribe M. Understanding the role of metabolic syndrome as a risk factor for hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:583–593. doi:10.2147/JHC.S283840
   PubMed Web of Science ®Google Scholar
• Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158(7):1899–1912. doi:10.1053/j.gastro.2019.12.054
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61(1):75–81. doi:10.1016/j.jhep.2014.02.030
   PubMed Web of Science ®Google Scholar
• Carlsson B, Linden D, Brolen G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305–1320. doi:10.1111/apt.15738
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Shima T, Mizuno M, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS One. 2018;13(1):e0185490. doi:10.1371/journal.pone.0185490
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883–1894. doi:10.1002/hep.24283
   PubMed Web of Science ®Google Scholar
• Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(3):325–334. doi:10.1038/ajg.2013.476
   PubMed Web of Science ®Google Scholar
• Shen J, Wong GL, Chan HL, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014;39(5):532–539. doi:10.1111/apt.12609
   PubMed Web of Science ®Google Scholar
• Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):1209–1217. doi:10.1002/hep.23622
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–1465. doi:10.1038/ng.257
   PubMed Web of Science ®Google Scholar
• Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019;50(2):144–158. doi:10.1111/apt.15314
   PubMed Web of Science ®Google Scholar
• Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054–1062 e1055. doi:10.1016/j.cmet.2017.04.001
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–947. doi:10.1016/j.jhep.2013.12.019
   PubMed Web of Science ®Google Scholar
• Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64. doi:10.1038/nature13568
   PubMed Web of Science ®Google Scholar
• Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study. Clin Gastroenterol Hepatol. 2022;20(6):1374–1381 e1376. doi:10.1016/j.cgh.2021.07.016
   PubMed Web of Science ®Google Scholar
• Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016. J Intern Med. 2020;288(1):139–151. doi:10.1111/joim.13069
   PubMed Web of Science ®Google Scholar
• Li J, Henry L, Nguyen MH. Chronic hepatitis B and fatty liver-weal or woe? Am J Gastroenterol. 2022;117(4):688. doi:10.14309/ajg.0000000000001644
   PubMed Web of Science ®Google Scholar
• Li J, Yang HI, Yeh ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224(2):294–302. doi:10.1093/infdis/jiaa739
   PubMed Web of Science ®Google Scholar
• Mao X, Cheung KS, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology. 2022. doi:10.1002/hep.32792
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378e365; quiz e314–365. doi:10.1053/j.gastro.2015.04.005
   Web of Science ®Google Scholar
• Baumeister SE, Schlesinger S, Aleksandrova K, et al. Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study. J Hepatol. 2019;70(5):885–892. doi:10.1016/j.jhep.2018.12.014
   PubMed Web of Science ®Google Scholar
• Turati F, Trichopoulos D, Polesel J, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol. 2014;60(3):606–611. doi:10.1016/j.jhep.2013.10.034
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Vuppalanchi R, Desai AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2019;50(3):317–328. doi:10.1111/apt.15331
   PubMed Web of Science ®Google Scholar
• Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62(4):606–615. doi:10.1136/gutjnl-2011-301708
   PubMed Web of Science ®Google Scholar
• Kramer JR, Natarajan Y, Dai J, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022;75(6):1420–1428. doi:10.1002/hep.32244
   PubMed Web of Science ®Google Scholar
• Zou B, Odden MC, Nguyen MH. Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;21(2):435–444.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495–509. doi:10.1002/hep.30368
   PubMed Web of Science ®Google Scholar
• Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018;4(12):1683–1690. doi:10.1001/jamaoncol.2018.4154
   PubMed Web of Science ®Google Scholar
• Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(13):2776–2784 e2774. doi:10.1016/j.cgh.2019.04.061
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer (IARC). Available from: https://www.iarc.who.int. Accessed February 27, 2023.
   Google Scholar
• Safiri S, Nejadghaderi SA, Karamzad N, et al. Global, regional, and national cancer deaths and disability-adjusted life-years (DALYs) attributable to alcohol consumption in 204 countries and territories, 1990–2019. Cancer. 2022;128(9):1840–1852. doi:10.1002/cncr.34111
   PubMed Web of Science ®Google Scholar
• Global health data exchange GBD 2019. Available from: https://vizhub.healthdata.org/gbd-results/. Accessed February 27, 2023.
   Google Scholar
• Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• WHO global information system on alcohol and health. Available from: https://apps.who.int/gho/data/node.main.GISAH. Accessed February 27, 2023.
   Google Scholar
• Hagstrom H, Thiele M, Sharma R, et al. Risk of cancer in biopsy-proven alcohol-related liver disease: a population-based cohort study of 3410 persons. Clin Gastroenterol Hepatol. 2022;20(4):918–929 e918. doi:10.1016/j.cgh.2021.01.005
   PubMed Web of Science ®Google Scholar
• Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7(8):599–612. doi:10.1038/nrc2191
   PubMed Web of Science ®Google Scholar
• Huang DQ, Tan DJH, Ng CH, et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022. doi:10.1016/j.cgh.2022.06.032
   Web of Science ®Google Scholar
• Pearson MM, Kim NJ, Berry K, et al. Associations between alcohol use and liver-related outcomes in a large national cohort of patients with cirrhosis. Hepatol Commun. 2021;5(12):2080–2095. doi:10.1002/hep4.1776
   PubMed Web of Science ®Google Scholar
• Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437–445. doi:10.1111/j.1465-3362.2009.00153.x
   PubMed Web of Science ®Google Scholar
• Roerecke M, Vafaei A, Hasan OSM, et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. Am J Gastroenterol. 2019;114(10):1574–1586. doi:10.14309/ajg.0000000000000340
   PubMed Web of Science ®Google Scholar
• Tan DJH, Setiawan VW, Ng CH, et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology. 2022. doi:10.1002/hep.32758
   Web of Science ®Google Scholar
• Acuff SF, Strickland JC, Tucker JA, Murphy JG. Changes in alcohol use during COVID-19 and associations with contextual and individual difference variables: a systematic review and meta-analysis. Psychol Addict Behav. 2022;36(4):386. doi:10.1037/adb0000852
   PubMed Web of Science ®Google Scholar
• Kilian C, O’Donnell A, Potapova N, et al. Changes in alcohol use during the COVID-19 pandemic in Europe: a meta-analysis of observational studies. Drug Alcohol Rev. 2022;41(4):918–931. doi:10.1111/dar.13446
   PubMed Web of Science ®Google Scholar
• Plata A, Motoki K, Spence C, Velasco C. Trends in alcohol consumption in relation to the COVID-19 pandemic: a cross-country analysis. Int J Gastron Food Sci. 2022;27:100397. doi:10.1016/j.ijgfs.2021.100397
   PubMed Web of Science ®Google Scholar
• Pollard MS, Tucker JS, Green HD. Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US. JAMA Netw Open. 2020;3(9):e2022942. doi:10.1001/jamanetworkopen.2020.22942
   PubMed Web of Science ®Google Scholar
• Weerakoon SM, Jetelina KK, Knell G. Longer time spent at home during COVID-19 pandemic is associated with binge drinking among US adults. Am J Drug Alcohol Abuse. 2021;47(1):98–106. doi:10.1080/00952990.2020.1832508
   PubMed Web of Science ®Google Scholar
• Julien J, Ayer T, Tapper EB, Barbosa C, Dowd WN, Chhatwal J. Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study. Hepatology. 2022;75(6):1480–1490. doi:10.1002/hep.32272
   PubMedGoogle Scholar
• Gao X, Lv F, He X, et al. Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States. J Hepatol. 2022;78(1):16–27.
   PubMed Web of Science ®Google Scholar
• Costentin CE, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study. Cancer. 2018;124(9):1964–1972. doi:10.1002/cncr.31215
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Gonzalez-Dieguez ML, Varela M, et al. Impact of alcohol abstinence on the risk of hepatocellular carcinoma in patients with alcohol-related liver cirrhosis. Am J Gastroenterol. 2021;116(12):2390–2398. doi:10.14309/ajg.0000000000001399
   PubMed Web of Science ®Google Scholar
• Lackner C, Spindelboeck W, Haybaeck J, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–618. doi:10.1016/j.jhep.2016.11.011
   PubMed Web of Science ®Google Scholar
• Hosseini N, Shor J, Szabo G. Alcoholic hepatitis: a review. Alcohol Alcohol. 2019;54(4):408–416. doi:10.1093/alcalc/agz036
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Nagy LE. Natural history of alcohol-associated liver disease: understanding the changing landscape of pathophysiology and patient care. Gastroenterology. 2022;163(4):840–851. doi:10.1053/j.gastro.2022.05.031
   PubMed Web of Science ®Google Scholar
• Liu SY, Tsai IT, Hsu YC. Alcohol-related liver disease: basic mechanisms and clinical perspectives. Int J Mol Sci. 2021;22(10):5170.
   PubMed Web of Science ®Google Scholar